CR11479A - Piperazinas como agentes antiobesidad - Google Patents

Piperazinas como agentes antiobesidad

Info

Publication number
CR11479A
CR11479A CR11479A CR11479A CR11479A CR 11479 A CR11479 A CR 11479A CR 11479 A CR11479 A CR 11479A CR 11479 A CR11479 A CR 11479A CR 11479 A CR11479 A CR 11479A
Authority
CR
Costa Rica
Prior art keywords
piperazinas
compounds
antiobesity agents
preparation
dyslipidemias
Prior art date
Application number
CR11479A
Other languages
English (en)
Inventor
Joseph Boyd
Giles A Brown
Michael Higginbottom
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CR11479A publication Critical patent/CR11479A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invencion se refiere a nuevos compuestos de formula (I), a composiciones farmaceuticas que comprenden estos compuestos, a procesos para su preparacion y al uso de estos compuestos como mimeticos moduladores del receptor de leptina en la preparacion de medicamentos para afecciones asociadas con el aumento de peso, la diabetes tipo 2 y las dislipidemias.
CR11479A 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad CR11479A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0702696 2007-12-05
US2298308P 2008-01-23 2008-01-23

Publications (1)

Publication Number Publication Date
CR11479A true CR11479A (es) 2010-07-19

Family

ID=40409928

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11479A CR11479A (es) 2007-12-05 2010-06-04 Piperazinas como agentes antiobesidad

Country Status (17)

Country Link
US (3) US7851471B2 (es)
EP (1) EP2229362A1 (es)
JP (1) JP2011506294A (es)
KR (1) KR20100093104A (es)
CN (1) CN102026975A (es)
AU (1) AU2008333173A1 (es)
BR (1) BRPI0819989A2 (es)
CA (1) CA2707555A1 (es)
CO (1) CO6280487A2 (es)
CR (1) CR11479A (es)
DO (1) DOP2010000167A (es)
EA (1) EA201000926A1 (es)
EC (1) ECSP10010234A (es)
IL (1) IL205874A0 (es)
MX (1) MX2010006259A (es)
WO (1) WO2009071658A1 (es)
ZA (1) ZA201003976B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240447A2 (en) * 2007-12-05 2010-10-20 AstraZeneca AB (Publ) Morpholine derivates as antiobesity agents
ATE546441T1 (de) * 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
KR101810975B1 (ko) * 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
EP2683716A1 (en) 2011-03-11 2014-01-15 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
US11807622B2 (en) 2019-01-30 2023-11-07 Insilico Medicine Ip Limited TLR 9 inhibitors
US10689360B1 (en) * 2019-01-30 2020-06-23 Insilico Medicine Ip Limited TLR inhibitors
CN113149891B (zh) * 2020-01-07 2024-02-02 南京药石科技股份有限公司 一种2-氨基-2-（1-甲基-4-哌啶基）乙醇的制备方法
CN117777048B (zh) * 2023-09-25 2024-09-20 上海科利生物医药有限公司 一种手性2-羟甲基吗啉-4-羧酸叔丁酯的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3420193A1 (de) * 1984-05-30 1985-12-05 Boehringer Ingelheim KG, 6507 Ingelheim Neue substituierte pyrrolidinone, verfahren zu ihrer herstellung und arzneimittel
KR20000016402A (ko) 1996-06-06 2000-03-25 피터 기딩스 렙틴(ob단백질)의 프레그먼트
TW434220B (en) * 1998-02-02 2001-05-16 Shiseido Co Ltd 1,2-di-substituted piperidine derivative, a hair growth agent, and an agent for external use to the skin
JP2001131149A (ja) 1999-11-08 2001-05-15 Sumitomo Pharmaceut Co Ltd 選択的セロトニン再取り込み阻害剤
JP2001261657A (ja) 2000-03-17 2001-09-26 Yamanouchi Pharmaceut Co Ltd シアノフェニル誘導体
CZ20031194A3 (cs) 2000-09-29 2003-08-13 Glaxo Group Limited Deriváty močoviny
ES2197003B1 (es) * 2002-04-08 2005-03-16 J. URIACH & CIA S.A. Nuevos compuestos antagonistas de integrinas alfa.
AU2004265243A1 (en) 2003-06-20 2005-02-24 Arena Pharmaceuticals, Inc. N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c receptor associated diseases
WO2006060461A1 (en) * 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
DE102005000666B3 (de) 2005-01-04 2006-10-05 Sanofi-Aventis Deutschland Gmbh Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20090325975A1 (en) 2005-07-15 2009-12-31 Helmut H Buschmann Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
EP1787679A1 (en) 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7790726B2 (en) 2005-08-16 2010-09-07 Chemocentryx, Inc. Monocyclic and bicyclic compounds and methods of use
US20090181976A1 (en) 2006-02-28 2009-07-16 Buschmann Helmut H Use of Compounds Binding to the Sigma Receptor for the Treatment of Metabolic Syndrome
ATE546441T1 (de) 2007-12-05 2012-03-15 Astrazeneca Ab Piperazinderivate und ihre verwendung als modulatoren des leptinrezeptors
CN102026993A (zh) 2007-12-05 2011-04-20 阿斯利康(瑞典)有限公司 新化合物iii
EP2240447A2 (en) 2007-12-05 2010-10-20 AstraZeneca AB (Publ) Morpholine derivates as antiobesity agents
AU2009254552A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab (Publ) New pyridine derivatives as leptin receptor modulator mimetics
AU2009254557A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab (Publ) Small molecule leptin receptor modulators
EP2321276A1 (en) 2008-06-04 2011-05-18 AstraZeneca AB New compounds vii
CA2725949A1 (en) 2008-06-04 2009-12-10 Astrazeneca Ab New pyridine derivatives as leptin receptor modulator mimetics

Also Published As

Publication number Publication date
EA201000926A1 (ru) 2011-02-28
US20110059969A1 (en) 2011-03-10
CN102026975A (zh) 2011-04-20
KR20100093104A (ko) 2010-08-24
US20110046135A1 (en) 2011-02-24
IL205874A0 (en) 2010-11-30
DOP2010000167A (es) 2010-06-30
MX2010006259A (es) 2010-08-23
AU2008333173A1 (en) 2009-06-11
CO6280487A2 (es) 2011-05-20
BRPI0819989A2 (pt) 2015-05-12
US7851471B2 (en) 2010-12-14
US20090181967A1 (en) 2009-07-16
JP2011506294A (ja) 2011-03-03
EP2229362A1 (en) 2010-09-22
ZA201003976B (en) 2011-04-28
ECSP10010234A (es) 2010-07-30
WO2009071658A1 (en) 2009-06-11
CA2707555A1 (en) 2009-06-11

Similar Documents

Publication Publication Date Title
CO6280487A2 (es) Piperazinas como agentes antiobesidad
CL2008002787A1 (es) Compuestos derivados de piperidina, que presentan actividad moduladora sobre la actividad del receptor gpr 119; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades tales como diabetes tipo 1 y 2, hiperllpidemia, enfermedad coronaria, obesidad y disfuncion erectil.
CR11801A (es) Derivados de indazol sustituidos con fenilo y benzodioxinilo
CR11455A (es) Compuestos nuevos de hidrocarbono ciclico para el tratamiento de enfermedades
CR10922A (es) Derivados de indol como antagonistas receptores de s1p1
SV2010003580A (es) Agonistas novedosos de los receptores de glucocorticoides
UY31080A1 (es) Derivados de pirazol sustituidos con heteroarilo utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
UY30470A1 (es) Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones.
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
CO6480948A2 (es) Composición farmacéutica para la anticoncepción de emergencia
CR10497A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor gpr38
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
ECSP099425A (es) Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2
CO6341625A2 (es) Derivados de indol como agentes anticáncer
CR9722A (es) Derivados de benzilpiperazina y su uso medico
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
PA8773601A1 (es) Agonistas cannabinoides de bencimidazol
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.
BRPI0815455C1 (pt) compostos derivados de n-fenilacetamida, composição farmacêutica, composição cosmética, uso cosmético de uma composição, e usos de um composto do mesmo
MX2010006215A (es) Derivados de piperazina y su uso como moduladores del receptor de leptina.
ECSP067028A (es) Profármacos de esteroides con acción androgénica
CU20100116A7 (es) Piperazinas como agentes antiobesidad
MX2010006220A (es) Derivados de morfolina como agentes antiobesidad.
DOP2007000120A (es) Derivados de imminoimidazopiridina que tienen actividad antitrombotica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)